肿瘤坏死因子α与卵巢癌化疗耐药

Tumor necrosis factor α and drug-resistance in chemotherapy for ovarian cancer

卵巢癌是女性四大癌症死亡原因之一 ,目前的治疗方法是手术加化疗 ,有效率达 80 % ,但由于耐药的出现 ,使卵巢癌预后不良 ,5年存活率在 30 %左右。近来 ,肿瘤坏死因子α作为卵巢癌化疗的辅助用药 ,引起人们的注意 ,而且越来越多的实验表明 ,其作为细胞因子 ,能有效逆转多药耐药 ,增加化疗药特别是以拓扑异构酶Ⅱ为作用点的化疗药的疗效。其优点是 :逆转耐药所需剂量小 ,存在时间 效应和剂量 效应关系等。

Ovarian cancer is one of the four major causes of cancer related deaths in women and at present therapeutic approach to this disease such as surgery plus chemotherapy, have produced an effective rate of up to 80%,however, the prognosis of ovarian cancer is poor because of drug resistance, the five year survival rate remains approximately 30%.Recently, tumor necrosis facter α ( TNF) has attracted the chinicians' attention as an adjuvant for chemotherapy of ovarian cancer. More and more experiments have showed that as a cytokine, TNFα can effectively reverses multidrug resistance, furthermore, it can enhance the effects of same kind of chemotherapeutic agents, especially those targeting to DNA topoisomerase Ⅱ. The adventages of the TNFα are that it needs only a small doses to reverse drug resistance, and there are time effect and dose effect relations. The following article comprehensively reviewed the effects of TNFα on reversion of drug resistance in chemotherapy for ovarian cancer.